Patents Examined by Prema Mertz
  • Method for the treatment of glomerulonephritis by administering an IL-6 antibody
    Patent number: 9321837
    Abstract: The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: April 26, 2016
    Assignee: UCB PHARMA S.A.
    Inventors: Diane Marshall, Stevan Shaw
  • Method of treating eosinophilia by administering an immunomodulating peptide
    Patent number: 9315544
    Abstract: A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: April 19, 2016
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Lin-Shien Fu, Shun-Lung Fang
  • Method of treating rheumatoid arthritis with an anti-IL-6R antibody
    Patent number: 9308256
    Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: April 12, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • sGCalphal inhibiting compositions
    Patent number: 9301991
    Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: April 5, 2016
    Assignee: The University of Toledo
    Inventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
  • Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
    Patent number: 9301997
    Abstract: The present invention relates to a pharmaceutical composition comprising as active substance, at least one compound comprising, or consisting of, a polypeptide which comprises, or consists of, at least 11 contiguous amino acids selected from X1-S-D-I-F-X2-G-E-P-X3-L-X4-P-X5-X6-X7-X8-X9-Q-L (SEQ ID NO: 13).
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: April 5, 2016
    Assignee: PEPTINOV SAS
    Inventors: Jean-François Zagury, Rojo Ratsimandresy
  • Treatment of cancers with A-8R peptide
    Patent number: 9295686
    Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: March 29, 2016
    Assignee: The University of Toledo
    Inventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
  • Methods of stimulating fat mobilization using a polymer conjugated polyphenol
    Patent number: 9272049
    Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: March 1, 2016
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Maria Alexander-Bridges, Shaker A. Mousa, Paul J. Davis
  • Antibodies to matrix metalloproteinase 9
    Patent number: 9260532
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: February 16, 2016
    Assignee: Gilead Biologics, Inc.
    Inventors: Scott McCauley, Maria Vaysberg
  • Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
    Patent number: 9260516
    Abstract: The present inventors studied the effects of inhibiting the IL-6 signaling pathway on muscle cell growth. As a result, they discovered that, administering an IL-6 inhibitor can promote the adhesion, proliferation, and differentiation of satellite cells and therefore muscle regeneration.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: February 16, 2016
    Assignee: Osaka University
    Inventors: Norihiro Nishimoto, Yoshinobu Ohira
  • Bi-specific fusion proteins
    Patent number: 9238080
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: January 19, 2016
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Induction of IL-12 using immunotherapy
    Patent number: 9233156
    Abstract: The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: January 12, 2016
    Assignee: IMMUNOVATIVE THERAPIES LTD.
    Inventor: Michael Har-Noy
  • Antibodies to interleukin-6
    Patent number: 9234035
    Abstract: The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 12, 2016
    Assignee: Fountain Biopharma Inc.
    Inventors: Tong-Young Lee, Han-Chung Wu, Tanny Chen Tsao, Willie Lin
  • Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodies
    Patent number: 9234034
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: January 12, 2016
    Assignee: NOVIMMUNE S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Antibodies against human CSF-1R
    Patent number: 9221910
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: December 29, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • ZCYTOR17 heterodimeric cytokine receptor
    Patent number: 9212213
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: December 15, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Method of lowering mortality
    Patent number: 9205132
    Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: December 8, 2015
    Assignee: CORTHERA, INC.
    Inventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
  • Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof
    Patent number: 9206252
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: December 8, 2015
    Assignee: XOMA (US) LLC
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
    Patent number: 9181317
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 10, 2015
    Assignee: SCOTT & WHITE MEMORIAL HOSPITAL
    Inventor: Arthur E. Frankel
  • Biomaterial for wound healing
    Patent number: 9173969
    Abstract: The present invention provides a biomaterial comprising a scaffold consisting of collagen, hyaluronic acid, and gelatin, which are cross-linked via ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) between any two of collagen, hyaluronic acid, and gelatin. The present invention further provides a method for preparing the biomaterial and a method for enhancing wound healing with the biomaterial.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: November 3, 2015
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Hui-Min Wang, Mei-Ling Ho, Gwo-Jaw Wang, Je-Ken Chang, Yi-Ting Chou, Ching-Ying Wu, Su-Shin Lee
  • Antibodies to bone marrow stromal antigen 1
    Patent number: 9175092
    Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 3, 2015
    Assignee: OXFORD BIOTHERAPEUTICS LTD
    Inventors: Christian Rohlff, Jonathan Alexander Terrett